immunotherapy

September 7, 2021 · Richard L. Schilsky, MD, FACP, FSCT, FASCO
Algunas aprobaciones recientes de la Administración de Alimentos y Medicamentos (Food and Drug Administration, FDA) han hecho que las personas se enteren de que hay tratamientos agnósticos con respecto a los tumores. Pero, ¿qué significa eso y cómo podría beneficiar a alguien con cáncer? El director médico anterior (2013-2021) de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica), Richard L. Schilsky, aporta información sobre esta nueva forma de abordar el tratamiento del cáncer. Read More >>
2021 ASCO Annual Meeting; #ASCO21
August 5, 2021 · Brielle Gregory Collins, ASCO staff
In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting in lung cancer, breast cancer, and sarcoma and describe what this research means for people with cancer. Read More >>
June 17, 2021 · Craig A. Portell, MD
Dr. Craig A. Portell discusses what CAR T-cell therapy is, how it works, what its common side effects are, and how it’s changing the landscape of how some types of cancers are treated. Read More >>
2021 ASCO Annual Meeting; #ASCO21
June 3, 2021 · ASCO Staff
The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer. Read More >>
2021 ASCO Annual Meeting; #ASCO21
May 19, 2021 · ASCO Staff
Read early research highlights just released for the 2021 ASCO Annual Meeting. Topics include immunotherapy for melanoma and non-small cell lung cancer, PSA screening for prostate cancer, HPV vaccination, and Medicaid income eligibility limits. Read More >>

Pages